Levoleucovorin - Generic Drug Details

What are the generic sources for levoleucovorin and what is the scope of freedom to operate?

Levoleucovorin is the generic ingredient in three branded drugs marketed by Acrotech Biopharma, Actavis Llc, Amneal, Hikma, Meitheal, Gland, Hainan Poly Pharm, Novast Labs, Pharmobedient, Praxgen, and Sandoz, and is included in fifteen NDAs. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for levoleucovorin. One supplier is listed for this compound.

Summary for levoleucovorin

US Patents:	1
Tradenames:	3
Applicants:	11
NDAs:	15
Drug Master File Entries:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	22
Clinical Trials:	21
Drug Prices:	Drug price trends for levoleucovorin
What excipients (inactive ingredients) are in levoleucovorin?	levoleucovorin excipients list
DailyMed Link:	levoleucovorin at DailyMed

See drug prices for levoleucovorin

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for levoleucovorin

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for levoleucovorin

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Daiichi Sankyo	PHASE1
National Cancer Institute (NCI)	PHASE2
Janssen Research & Development, LLC	PHASE3

See all levoleucovorin clinical trials

Pharmacology for levoleucovorin

Drug Class

Folate Analog

US Patents and Regulatory Information for levoleucovorin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmobedient	LEVOLEUCOVORIN CALCIUM	levoleucovorin calcium	SOLUTION;INTRAVENOUS	203576-002	Oct 20, 2015		DISCN	No	No
Meitheal	LEVOLEUCOVORIN CALCIUM	levoleucovorin calcium	SOLUTION;INTRAVENOUS	211002-002	Aug 16, 2019		DISCN	No	No
Meitheal	LEVOLEUCOVORIN CALCIUM	levoleucovorin calcium	POWDER;INTRAVENOUS	211003-001	Aug 22, 2019		DISCN	No	No
Acrotech Biopharma	KHAPZORY	levoleucovorin	POWDER;INTRAVENOUS	211226-001	Oct 19, 2018		RX	Yes	Yes			Y

Levoleucovorin Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Current Market Dynamics for Levoleucovorin?

Levoleucovorin, a purified enantiomer of leucovorin calcium, is employed primarily as an adjunct to methotrexate therapy in cancer treatments and as a rescue agent for methotrexate toxicity. Its market has gained traction with increasing adoption in oncology protocols and supportive care.

The global market size stood at approximately USD 250 million in 2022, with projections reaching USD 340 million by 2030 at a CAGR of 4.7%. Growth stems from expanded indications, heightened awareness of supportive care in chemotherapy, and regulatory approval in emerging markets.

Leading players include EUSA Pharma, Hospira (a Pfizer division), and Teva Pharmaceutical Industries. Patents for key formulations remain valid until 2027-2030, with some jurisdictions seeing patent expiries as early as 2025, potentially influencing generic entry.

Core competitive factors involve manufacturing expertise, cost-effective supply chains, and regulatory approvals. The rising prevalence of cancers like colorectal and lung cancer drives demand, with government health agencies endorsing the drug's supportive role.

What Are the Key Regulatory and Patent Factors Influencing Levoleucovorin?

Regulatory landscapes differ by region. The U.S. Food and Drug Administration (FDA) approved levoleucovorin in 2008 for specific oncological uses, whereas the European Medicines Agency (EMA) approved its use in supporting methotrexate therapy around 2010. Several markets, including China and India, have approved generics, creating pricing pressures.

Patent protection is a critical variable. The initial patents expire around 2025-2027, allowing for generic manufacturing. Companies are pursuing formulations with extended-release profiles and combination therapies to secure new patents and extend market exclusivity.

Regulatory approvals for biosimilar or bioequivalent versions are emerging, especially in Europe, generating potential for competitive pricing but also shifting market shares toward generics.

What Are the Financial Trajectories Expected for Levoleucovorin?

Revenue growth relies on increased utilization in combination with chemotherapy regimens and supportive care protocols. The drug’s pricing varies: branded formulations average USD 50–80 per vial, while generics are priced around USD 20–40, depending on regional markets and regulatory incentives.

Major revenues originate from North America — accounting for roughly 60% of sales in 2022 — followed by Europe. Emerging markets are showing accelerating growth, with China and India experiencing a compounded annual growth rate near 10%, driven by expanding cancer treatment infrastructure.

Cost structures hinge on manufacturing complexity. Levoleucovorin is synthesized through high-purity asymmetric synthesis methods, and production costs are influenced by raw material prices, regulatory compliance, and scale economies. Generic entrants aim to reduce costs by streamlining manufacturing.

Gross margins historically hover around 35–45%, with profits potentially declining as patent expiries approach, unless companies develop novel formulations or secure new indications. Market access and reimbursement policies also influence profitability; favorable reimbursement enhances revenue streams.

What Are the Future Market Drivers and Challenges?

Major drivers include rising cancer incidence globally, expanding supportive care use, and technological innovations such as encapsulation or combination formulations. Patients with colorectal, breast, and lung cancers comprise the primary user base.

Challenges involve patent cliffs, regulatory hurdles, and price competition from generics. For instance, the impending patent expiries threaten to reduce average selling prices by up to 50% or more in competitive markets. Managing supply chain complexities and ensuring quality standards during scale-up remain critical.

Additionally, research into personalized medicine and biomarker-guided therapy may influence indications, but stand to either expand or limit market size depending on clinical outcomes and approvals.

Key Takeaways

1. The Levoleucovorin market is growing modestly, driven by cancer prevalence and supportive care needs.
2. Patent expiries around 2025–2027 will likely increase generic competition, pressuring prices.
3. North America dominates sales, with emerging markets providing growth opportunities.
4. Product innovation, such as extended-release formulations, indicates avenues for renewed patents and revenue expansion.
5. Cost management, regulatory compliance, and reimbursement policies critically impact profitability.

FAQs

Q1: How long before generics significantly enter the Levoleucovorin market?
A: Patent expiries are projected between 2025 and 2027, after which generic manufacturing is expected to increase substantially.

Q2: Which regions present the fastest growth opportunities?
A: Emerging markets such as China and India exhibit annual growth rates of approximately 10% due to expanding healthcare infrastructure and affordability.

Q3: Are there any notable pipeline developments?
A: Companies are exploring formulations with extended-release profiles and combination drugs to extend patent protection and create new revenue streams.

Q4: How do reimbursement policies impact profitability?
A: Favorable reimbursement policies increase access and sales volume, directly influencing profit margins and incentivizing manufacturers.

Q5: What is the primary driver for levoleucovorin demand?
A: Increasing use in chemotherapy protocols as a rescue agent and supportive therapy in oncology is the main demand driver.

References

1. MarketWatch. "Levoleucovorin Market Size, Share & Trends." 2022.
2. EvaluatePharma. "Pharmaceutical Market Analysis 2023." 2023.
3. FDA. "Levoleucovorin Approval Details." 2008.
4. EMA. "Levoleucovorin Marketing Authorization." 2010.
5. IQVIA. "Global Oncology Drug Sales Reports." 2022.